MESA LABORATORIES, INC. (NASDAQ:MLAB) Files An 8-K Results of Operations and Financial ConditionITEM 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On February 5, 2018, Mesa Laboratories, Inc. issued a press release relating to its results for the three and nine months ended December 31, 2017. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished in Item 2.02 of this Current Report on Form8-K and Exhibit99.1 attached hereto shall not be deemed to be filed for the purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed to the Securities Act of 1933, as amended.
ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
(d) |
Exhibits: |
99.1 Press release dated February 5, 2018. |
MESA LABORATORIES INC /CO ExhibitEX-99.1 2 ex_104168.htm EXHIBIT 99.1 ex_104168.htm Exhibit 99.1 Mesa Labs Reports Third Quarter Results Lakewood,…To view the full exhibit click here
About MESA LABORATORIES, INC. (NASDAQ:MLAB)
Mesa Laboratories, Inc. is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products. Its Biological Indicators Division provides testing services, along with the manufacturing and marketing of biological indicators and distribution of chemical indicators used to assess the effectiveness of sterilization processes. Its Continuous Monitoring Division designs, develops and markets systems, which are used to monitor various environmental parameters. Its Cold Chain Division provides parameter (primarily temperature) monitoring of products in a cold chain. The Company’s brands include DataTrace, DialyGuard, DryCal, Torqo, SureTorque, BGI, Mesa, PCD, Apex, CheckPoint, Mesa and TempTrust.